Global Veterinary Pain Management Drugs Market - 2022-2029

Global Veterinary Pain Management Drugs Market - 2022-2029

Market Overview

The global veterinary pain management drugs market size was valued at US$ 1221.7 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Veterinary Pain Management Drugs refers to the medical services for the prevention, diagnosis, and treatment of diseases like Osteoarthritis, Postoperative pain, and Cancer in companion and livestock animals.

Market Dynamics

The global veterinary pain management drugs market growth is driven by the certain factors such as the rising prevalence of painful and inflammatory diseases in animals, increasing initiatives towards animal healthcare and increasing number of companion animal ownership.

The increasing government initiative towards animal healthcare, is expected to drive the global veterinary pain management drugs market during the forecast period

In November 2019, the Global Pain Council (GPC) of the World Small Animal Veterinary Association (WSAVA) has launched a program called ‘Teach the Teachers,’ which aims to create a global network of key opinion leaders (KOLs) – ‘teachers’ – in pain management, who are motivated to propagate and disseminate their knowledge within their regions.

In March 2020, Ceva Animal Health, the manufacturer of Ketofen 10%, has launched a ‘Wave Goodbye to Pain’ campaign to highlight the positive impact of pain relief on lame cattle and the role it can play in improving recovery time and results. The initiative was launched following a study by Nottingham University which revealed that NSAIDs (anti-inflammatory and pain-relieving injections) have a synergistic (greater than simply additive) effect when given alongside effective hoof trimming and blocking to treat lameness. The findings have emerged alongside a second study showing that over the last 10 years, farmers are increasingly aware of the need for pain relief and 52% are happy to pay the extra costs involved (up from 36% in 2006).

Changes in distribution channel are likely to hinder the market growth

Generally, companion animal owners purchase their animal health products directly from veterinarians. Companion animal owners has changed their purchase pattern and shifted the focus towards internet-based retailers, retail stores, or other over-the-counter distribution channels. This shift is leading the companion health owners to opt for substitute human health products for animal health products if human health products are deemed to be lower-cost alternatives.

Moreover, consolidation of primary customers such as veterinarians might adversely affect price of companion healthcare products. Further, low-cost generic product subtitles and their increased usage might hamper the market potential. Restrictions by regulatory bodies might have a negative impact on the sales of pain relief drugs. Increasing costs of companion healthcare and increasing regulations on animal testing might further hamper the market.

Moreover, lack of infrastructure may also make it difficult to transport medicines and vaccines to where they are required because of poor transport links, lack of refrigeration, and networks of laboratories for conducting health tests. Change in purchase patterns, increased generic drugs, low-cost human drug sublimities, and regulatory restriction are key factors which might restrain the market growth significantly.

COVID-19 Impact Analysis

The COVID-19 outbreak has impacted all global industries, including veterinary pain medicine. Pet parents are advised to keep a safe distance from their pets to maintain hygiene and reduce the risk of contamination. Moreover, the impact has been seen in the livestock sector. Moving animal products, such as meat, milk, and eggs, has been trouble moving to markets. The restriction has been implemented on the seasonal border crossing with ruminants. For example, in April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and the supply chain of livestock products during the COVID-19 pandemic.

Segment Analysis

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Non-steroidal anti-inflammatory drugs are one of the most commonly used and most effective drug in the treatment of pain due to arthritis or after surgery in dogs and cats. Rimadyl, Metacam, Dermaxx, Etogesic, among others comes under this class of drugs. NSAIDS act by inhibiting inflammatory substances called prostaglandins (PGEs), which cause pain, inflammation, and fever. Hence they are called ‘anti-inflammatory’ but their main purpose is pain control (inflammation is how pain starts). These drugs are readily available, relatively long-acting, and generally inexpensive. They can also be given at home after an animal has been released from the hospital. For these reasons, they have long been used for pain relief. Veterinarians may prescribe NSAIDs as one part of the total plan for pain relief, provided the animal does not have kidney, liver, blood clotting, or stomach problems.

However, some side effects can occur, with the most common being gastrointestinal (GI) disturbance (symptoms include vomiting, diarrhea, bloody or dark colored feces) from minor GI-ulcers. There is also risk of acute liver and/or kidney failure with all NSAIDs.

Geographical Analysis

North America region holds the largest market share of the global veterinary pain management drugs market

North America accounted for the largest share of the veterinary pain management market. Rise in the number of veterinarians across the world is believed spearhead current and future market growth of veterinary pain management drugs during the forecast period. For instance, according to the 2019-2020 National Pet Owners Survey, conducted by the American Pet Products Association (APPA), around 67% of the country’s households, or about 84.9 million families, own a pet. In addition, highly developed and well-established animal healthcare facilities is further fueling the growth.

Rising collective efforts by key players to improve their product portfolio and to ensure high-quality standards are projected to boost the regional demand. For instance, in May 2017, Norbrook launched chewable Carprieve tablets for dogs in a probe to expand its product portfolio.

In 2020, the United States Food & Drug Administration approved Cronus Pharma Specialties’ Carprofen Chewable Tablets (generic version of Rimadyl—Zoetis) for dogs. This nonsteroidal anti-inflammatory drug (NSAID) has been proven safe and effective in relieving pain and inflammation associated with osteoarthritis. Also, it helps control postoperative pain associated with soft tissue and orthopedic surgeries.

Competitive Landscape

The veterinary pain management drugs market is highly competitive and consists of a large number of players.

Some of the major players in the global veterinary pain management drugs market are Dechra Pharmaceuticals, Zoetis, Elanco, Boehringer Ingelheim, Vetoquinol S.A., Ceva Sante Animale S.A., Bayer AG, Merck Animal Health, Norbrook Laboratories, Chanelle Pharma, Virbac, among others. The key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence.

For instance, In April 2020, The UK Competition and Markets Authority or CMA Monday has launched a merger inquiry into Dechra Pharmaceuticals PLC's (DPH.L) anticipated acquisition of the Osurnia business of Elanco Animal Health Inc. (ELAN).

Key Companies to Watch

Zoetis Inc

Overview: Zoetis Inc. is a U.S. based animal health company involved in the production of medicine, vaccines, diagnostic products and other veterinary solutions. The company is considered as the global leader in veterinary vaccines market. The company is operating under three reportable segments – Livestock, Companion Animal and Contract manufacturing & human health. Zoetis’s Livestock business is responsible for the development, production and distribution of vaccines, anti-infective, paraciticides and medicated feed additives.

Product Portfolio: SIMBADOL (buprenorphine injection) offers continuous 24-hour surgical pain control for cats - even through the night.

The global veterinary pain management drugs market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.